Gyre Therapeutics, Inc.
GYRE
$7.64
$0.060.79%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 14.17% | 21.37% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 14.17% | 21.37% | |||
| Cost of Revenue | 41.44% | 28.75% | |||
| Gross Profit | 12.94% | 21.05% | |||
| SG&A Expenses | -1.88% | 26.76% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.91% | 24.33% | |||
| Operating Income | 218.88% | -4.44% | |||
| Income Before Tax | 240.88% | -51.72% | |||
| Income Tax Expenses | 155.74% | -26.53% | |||
| Earnings from Continuing Operations | 276.65% | -57.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -105.11% | -9.46% | |||
| Net Income | 716.74% | -83.62% | |||
| EBIT | 218.88% | -4.44% | |||
| EBITDA | 169.29% | 0.18% | |||
| EPS Basic | 694.00% | -83.97% | |||
| Normalized Basic EPS | 796.67% | -86.05% | |||
| EPS Diluted | 1,486.36% | -48.84% | |||
| Normalized Diluted EPS | 803.85% | -85.71% | |||
| Average Basic Shares Outstanding | 1.94% | 3.12% | |||
| Average Diluted Shares Outstanding | 1.24% | 0.72% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||